Skip to main content
. 2022 Mar 8;7(5):e155260. doi: 10.1172/jci.insight.155260

Figure 5. PPKM2Tg mice showed improvement of glomerular mitochondrial function and glycolysis 7 months after STZ.

Figure 5

(A and C) OCR (A) and ECAR (C) in the glomeruli of WT and PPKM2Tg mice 7 months after STZ were measured by Seahorse. (B and D) The quantitated data from A and C. For OCR A and B, WT mice (n = 21); PPKM2Tg mice (n = 13); WT 7MSTZ mice (n = 11); Tg 7MSTZ mice (n = 13). *P < 0.05; **P < 0.01. For ECAR C and D, WT mice (n = 6); PPKM2Tg mice (n = 8); WT 7MSTZ mice (n = 4); Tg 7MSTZ mice (n = 6). *P < 0.05; **P < 0.01. Mouse recombinant VEGF (2 ng/mL), VEGF neutralizing antibody (anti-VEGF) (1 μg/mL), and premix of mVEGF with anti-VEGF were incubated for 2 hours in WT glomeruli. (E–H) OCR (E) and ECAR (G) were measured and quantitated data were presented (F and H). For OCR (E and F), control group (n = 14); mVEGF group (n = 7); anti-VEGF group (n = 6); mVEGF + anti-VEGF group (n = 5). *P < 0.05. For ECAR (G and H), control group (n = 7); mVEGF group (n = 8); anti-VEGF group (n = 3); mVEGF + anti-VEGF group (n = 5). **P < 0.01. Data are mean ± SEM, 2-way ANOVA followed by correction for multiple comparisons with Tukey’s post hoc test.